Associations - Yondelis (trabectedin)

No biomarker	Soft Tissue Sarcoma	No biomarker	Soft Tissue Sarcoma	trabectedin Sensitive: A1 - Approval trabectedin Sensitive : A1	trabectedin Sensitive: A1 - Approval trabectedin Sensitive : A1
No biomarker	Ovarian Cancer	No biomarker	Ovarian Cancer	trabectedin Sensitive: A1 - Approval trabectedin Sensitive : A1	trabectedin Sensitive: A1 - Approval trabectedin Sensitive : A1
No biomarker	Leiomyosarcoma	No biomarker	Leiomyosarcoma	trabectedin Sensitive: A1 - Approval trabectedin Sensitive : A1	trabectedin Sensitive: A1 - Approval trabectedin Sensitive : A1
No biomarker	Liposarcoma	No biomarker	Liposarcoma	trabectedin Sensitive: A1 - Approval trabectedin Sensitive : A1	trabectedin Sensitive: A1 - Approval trabectedin Sensitive : A1
No biomarker	Sarcoma	No biomarker	Sarcoma	trabectedin Sensitive: A2 - Guideline trabectedin Sensitive : A2	trabectedin Sensitive: A2 - Guideline trabectedin Sensitive : A2
No biomarker	Rhabdomyosarcoma	No biomarker	Rhabdomyosarcoma	trabectedin Sensitive: A2 - Guideline trabectedin Sensitive : A2	trabectedin Sensitive: A2 - Guideline trabectedin Sensitive : A2
BRCA2 mutation	Ovarian Cancer	BRCA2 mutation	Ovarian Cancer	trabectedin Sensitive: B - Late Trials trabectedin Sensitive : B	trabectedin Sensitive: B - Late Trials trabectedin Sensitive : B
BRCA1 mutation	Ovarian Cancer	BRCA1 mutation	Ovarian Cancer	trabectedin Sensitive: B - Late Trials trabectedin Sensitive : B	trabectedin Sensitive: B - Late Trials trabectedin Sensitive : B
CUL4A overexpression	Sarcoma	CUL4A overexpression	Sarcoma	doxorubicin hydrochloride + trabectedin Sensitive: C3 – Early Trials doxorubicin hydrochloride + trabectedin Sensitive : C3	doxorubicin hydrochloride + trabectedin Sensitive: C3 – Early Trials doxorubicin hydrochloride + trabectedin Sensitive : C3
ERCC5 overexpression	Sarcoma	ERCC5 overexpression	Sarcoma	doxorubicin hydrochloride + trabectedin Sensitive: C3 – Early Trials doxorubicin hydrochloride + trabectedin Sensitive : C3	doxorubicin hydrochloride + trabectedin Sensitive: C3 – Early Trials doxorubicin hydrochloride + trabectedin Sensitive : C3
ERCC1 overexpression	Sarcoma	ERCC1 overexpression	Sarcoma	doxorubicin hydrochloride + trabectedin Sensitive: C3 – Early Trials doxorubicin hydrochloride + trabectedin Sensitive : C3	doxorubicin hydrochloride + trabectedin Sensitive: C3 – Early Trials doxorubicin hydrochloride + trabectedin Sensitive : C3
CUL4A overexpression	Soft Tissue Sarcoma	CUL4A overexpression	Soft Tissue Sarcoma	trabectedin Sensitive: C3 – Early Trials trabectedin Sensitive : C3	trabectedin Sensitive: C3 – Early Trials trabectedin Sensitive : C3
ERCC5 overexpression	Soft Tissue Sarcoma	ERCC5 overexpression	Soft Tissue Sarcoma	trabectedin Sensitive: C3 – Early Trials trabectedin Sensitive : C3	trabectedin Sensitive: C3 – Early Trials trabectedin Sensitive : C3
ERCC1 overexpression	Soft Tissue Sarcoma	ERCC1 overexpression	Soft Tissue Sarcoma	trabectedin Sensitive: C3 – Early Trials trabectedin Sensitive : C3	trabectedin Sensitive: C3 – Early Trials trabectedin Sensitive : C3
LAG3 overexpression	Soft Tissue Sarcoma	LAG3 overexpression	Soft Tissue Sarcoma	trabectedin Sensitive: C3 – Early Trials trabectedin Sensitive : C3	trabectedin Sensitive: C3 – Early Trials trabectedin Sensitive : C3
CTLA4 overexpression	Soft Tissue Sarcoma	CTLA4 overexpression	Soft Tissue Sarcoma	trabectedin Sensitive: C3 – Early Trials trabectedin Sensitive : C3	trabectedin Sensitive: C3 – Early Trials trabectedin Sensitive : C3
PD-L1 expression	Soft Tissue Sarcoma	PD-L1 expression	Soft Tissue Sarcoma	trabectedin Sensitive: C3 – Early Trials trabectedin Sensitive : C3	trabectedin Sensitive: C3 – Early Trials trabectedin Sensitive : C3
HMGA1 overexpression	Soft Tissue Sarcoma	HMGA1 overexpression	Soft Tissue Sarcoma	trabectedin Resistant: C3 – Early Trials trabectedin Resistant : C3	trabectedin Resistant: C3 – Early Trials trabectedin Resistant : C3
PD-L1 overexpression	Sarcoma	PD-L1 overexpression	Sarcoma	trabectedin Sensitive: C3 – Early Trials trabectedin Sensitive : C3	trabectedin Sensitive: C3 – Early Trials trabectedin Sensitive : C3
PIK3CA mutation + TERT promoter mutation	Liposarcoma	PIK3CA mutation + TERT promoter mutation	Liposarcoma	trabectedin Resistant: C3 – Early Trials trabectedin Resistant : C3	trabectedin Resistant: C3 – Early Trials trabectedin Resistant : C3
EWSR1-FLI1 fusion	Ewing Sarcoma	EWSR1-FLI1 fusion	Ewing Sarcoma	trabectedin Sensitive: C3 – Early Trials trabectedin Sensitive : C3	trabectedin Sensitive: C3 – Early Trials trabectedin Sensitive : C3
BRCA2 mutation	Ovarian Cancer	BRCA2 mutation	Ovarian Cancer	pegylated liposomal doxorubicin + trabectedin Sensitive: C3 – Early Trials pegylated liposomal doxorubicin + trabectedin Sensitive : C3	pegylated liposomal doxorubicin + trabectedin Sensitive: C3 – Early Trials pegylated liposomal doxorubicin + trabectedin Sensitive : C3
BRCA1 mutation	Ovarian Cancer	BRCA1 mutation	Ovarian Cancer	pegylated liposomal doxorubicin + trabectedin Sensitive: C3 – Early Trials pegylated liposomal doxorubicin + trabectedin Sensitive : C3	pegylated liposomal doxorubicin + trabectedin Sensitive: C3 – Early Trials pegylated liposomal doxorubicin + trabectedin Sensitive : C3
EWSR1-WT1 fusion	Soft Tissue Sarcoma	EWSR1-WT1 fusion	Soft Tissue Sarcoma	trabectedin Sensitive: D – Preclinical trabectedin Sensitive : D	trabectedin Sensitive: D – Preclinical trabectedin Sensitive : D

Yondelis (trabectedin)

Associations
(24)

Associations
(24)

Yondelis (trabectedin)

Associations(24)

Associations(24)

Associations
(24)

Associations
(24)